Market Overview

Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH

Alnylam
Pharmaceuticals (Nasdaq: ALNY) announced today that it has presented new pre-clinical data
with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting
antithrombin (AT) for the treatment of hemophilia and rare bleeding
disorders (RBD), at the 55th Annual Meeting of the American
Society of Hematology (ASH) held December 7 – 10, 2013 in New Orleans.
In these new studies, repeat administration of ALN-AT3 was found to be
well tolerated in Hemophilia A (HA) mice, with no adverse findings up to
dose levels 200 times greater than levels required to achieve 50% AT
knockdown. Further, the new studies demonstrate that ALN-AT3
administration achieves complete correction of the activated Partial
Thromboplastin Time (aPTT)

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (ALNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters